Evidence map›Paper›PMID 42534456›Full record

ArticleOpen forum infectious diseases2026

Local Prevalence of Ceftriaxone Resistance Informs Optimal Deployment of New Gonorrhea Treatments.

Kirstin I Oliveira Roster, Minttu M Rönn, Eva R Gorenburg, Dennis K Partl, Nanina Anderegg, Pia Abel Zur Wiesch, Carmen Au, Roger D Kouyos, Fernando P Martinez, Nicola Low and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kirstin I Oliveira RosterDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0003-3468-2014
Minttu M RönnDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-9292-5670
Eva R GorenburgProgram in Human Biology, Stanford University, Stanford, California, USA.
Dennis K PartlInstitute of Medical Virology, University of Zurich, Zurich, Switzerland.
Nanina AndereggInstitute of Medical Virology, University of Zurich, Zurich, Switzerland.
Pia Abel Zur WieschDepartment of Pharmacy, University of Tromsø - The Arctic University of Norway, Tromsø, Norway.
Carmen AuGlobal Antibiotic Research and Development Partnership, Geneva, Switzerland.
Roger D KouyosInstitute of Medical Virology, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-9220-8348
Fernando P MartinezGlobal Antibiotic Research and Development Partnership, Geneva, Switzerland.
Nicola LowInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0003-4817-8986
Yonatan H GradDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0001-5646-1314

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Numerous factors may influence the optimal rollout of new gonococcal antibiotics. We compared 8 rollout strategies using a gonorrhea transmission model and ranked strategies by the number of gonococcal infections and clinically useful antibiotic lifespan. Rankings were most sensitive to the starting ceftriaxone resistance prevalence and screening frequency.

Indexed as

antibiotic stewardshipantimicrobial resistancegonorrheamathematical modelingsurveillance

Identifiers

PMID42534456
PMCPMC13420513

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.